²¹³ Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts

Abstract

²¹³Bi-PSMA I&T and ²¹³Bi-JVZ-008 showed efficient and rapid tumor targeting and produced DSBs in PSMA-expressing LNCaP cells and xenografts. These promising results require further evaluation of ²¹³Bi-labeled agents with regard to their therapeutic efficacy and toxicity for PCa therapy.